What Is Brown And White Fat.
A deaden already utilized to treat overactive bladder may also someday help control weight by boosting the metabolic powers of brown fat, a skimpy study suggests. While white fat stores energy, brown fertility burns energy to generate body heat. In the process, it can help make a stand for body weight and prevent obesity, at least in animals, previous studies have shown. In the unusual study, researchers gave 12 healthy, lean young men a high dose of the soporific mirabegron (Myrbetriq), and found that it boosted their metabolic rate. The drug "activates the brown heavy cells to burn calories and generate heat," said study researcher Dr Aaron Cypess.
He is segment head of translational physiology at the US National Institute of Diabetes and Digestive and Kidney Diseases. When the project of the drug peaked, "the metabolic rate went up by 13 percent on average. That translates to about 203 calories. However, Cypess said that doesn't automatically nasty the men would burn an extra 203 calories a day over the long-term. The researchers don't yet separate how long the calorie-burning effect might last, as they didn't follow the men over time.
The researchers projected the three-year incline loss would be about 22 pounds. The study was published Jan 6, 2015 in Cell Metabolism. The check out while working at the Joslin Diabetes Center and Harvard Medical School. The about was funded by the US National Institutes of Health, with no panacea company involvement. The men, whose average age was 22, took a separate dose of the drug in one session and took a single dose of a placebo in another, serving as their own comparisons.
The researchers regulated metabolic rate by scans, including positron emission tomography (PET) and CT scans. The chattels of the drug on fat-burning would be "mild to soften if sustained". The drug works by activating what is known as a beta 3-adrenergic receptor, found on the top of brown fat cells. It is also found on the urinary bladder cells, and the drug works to staid an overactive bladder by relaxing muscle cells there. Much more research is needed.
Showing posts with label research. Show all posts
Showing posts with label research. Show all posts
Thursday 13 June 2019
Thursday 30 May 2019
Decrease In Funding For Medical Research Can Have Serious Results
Decrease In Funding For Medical Research Can Have Serious Results.
Spending on medical fact-finding is waning in the United States, and this be biased could have dire consequences for patients, physicians and the robustness care industry as a whole, a new analysis reveals. America is losing territory to Asia, the research shows. And if left unaddressed, this decline in spending could ransack the world of cures and treatments for Alzheimer's disease, diabetes, depression and other conditions that irritate the human race, said lead author Dr Hamilton Moses III, originator and chairman of the Alerion Institute, a Virginia-based think tank.
A great expansion in medical research that began in the 1980s helped revolutionize cancer mitigating and treatment, and turned HIV/AIDS from a fatal bug to a chronic condition. But between 2004 and 2012, the rate of investment growth declined to 0,8 percent a year in the United States, compared with a nurturing rate of 6 percent a year from 1994 to 2004, the discharge notes. "Common diseases that are devastating are not receiving as much of a push as would be occurring if the earlier rank of investment had been sustained".
America now spends about $117 billion a year on medical research, which is about 4,5 percent of the nation's sum up health care expenses, the researchers report Jan 13, 2015 in the Journal of the American Medical Association. Cuts in rule funding are the absolute cause for flagging investment in research, they found. Meanwhile, the share of US medical research funding from withdrawn industry has increased to 58 percent in 2012, compared with 46 percent in 1994.
This has caused the United States' add up to share of global research funding - both social and private - to decline from 57 percent in 2004 to 44 percent in 2012, the communication noted. While the United States still maintains its preeminence in medical research, Asian countries daunt to take the lead. Asia - particularly China - tripled investment from $2,6 billion in 2004 to $9,7 billion in 2012, according to the report.
Spending on medical fact-finding is waning in the United States, and this be biased could have dire consequences for patients, physicians and the robustness care industry as a whole, a new analysis reveals. America is losing territory to Asia, the research shows. And if left unaddressed, this decline in spending could ransack the world of cures and treatments for Alzheimer's disease, diabetes, depression and other conditions that irritate the human race, said lead author Dr Hamilton Moses III, originator and chairman of the Alerion Institute, a Virginia-based think tank.
A great expansion in medical research that began in the 1980s helped revolutionize cancer mitigating and treatment, and turned HIV/AIDS from a fatal bug to a chronic condition. But between 2004 and 2012, the rate of investment growth declined to 0,8 percent a year in the United States, compared with a nurturing rate of 6 percent a year from 1994 to 2004, the discharge notes. "Common diseases that are devastating are not receiving as much of a push as would be occurring if the earlier rank of investment had been sustained".
America now spends about $117 billion a year on medical research, which is about 4,5 percent of the nation's sum up health care expenses, the researchers report Jan 13, 2015 in the Journal of the American Medical Association. Cuts in rule funding are the absolute cause for flagging investment in research, they found. Meanwhile, the share of US medical research funding from withdrawn industry has increased to 58 percent in 2012, compared with 46 percent in 1994.
This has caused the United States' add up to share of global research funding - both social and private - to decline from 57 percent in 2004 to 44 percent in 2012, the communication noted. While the United States still maintains its preeminence in medical research, Asian countries daunt to take the lead. Asia - particularly China - tripled investment from $2,6 billion in 2004 to $9,7 billion in 2012, according to the report.
Sunday 7 April 2019
Ecstasy In The Service Of Medicine
Ecstasy In The Service Of Medicine.
The recreational panacea known as nympholepsia may have a medicinal role to play in helping people who have trouble connecting to others socially, uncharted research suggests. In a study involving a small group of bracing people, investigators found that the drug - also known as MDMA - prompted heightened feelings of friendliness, playfulness and love, and induced a lowering of the protection that might have therapeutic uses for improving public interactions. Yet the closeness it sparks might not be result in deep and lasting connections.
The findings "suggest that MDMA enhances sociability, but does not by definition increase empathy," noted study author Gillinder Bedi, an helpmate professor of clinical psychology at Columbia University and a research scientist at the New York State Psychiatric Institute in New York City. The study, funded by the US National Institute on Drug Abuse and conducted at the Human Behavioral Pharmacology Laboratory at the University of Chicago, was published in the Dec 15 2010 originate of Biological Psychiatry.
In July, another den reported that MDMA might be advantageous in treating post-traumatic force disorder (PTSD), based on the drug's plain boosting of the ability to cope with grief by helping to control fears without numbing race emotionally. MDMA is part of a family of so-called "club drugs," which are popular with some teens and boyish at all night dances or "raves".
These drugs, which are often used in combination with alcohol, have potentially life-threatening effects, according to the US National Institute on Drug Abuse. The newest muse about explored the slang shit of MDMA on 21 healthy volunteers, nine women and 12 men elderly 18 to 38. All said they had taken MDMA for recreational purposes at least twice in their lives.
They were randomly assigned to board either a low or moderate dose of MDMA, methamphetamine or a sugar cough drop during four sessions in about a three-week period. Each session lasted at least 4,5 hours, or until all paraphernalia of the drug had worn off. During that time, participants stayed in a laboratory testing room, and common interaction was limited to contact with a research assistant who helped distribute cognitive exams.
The recreational panacea known as nympholepsia may have a medicinal role to play in helping people who have trouble connecting to others socially, uncharted research suggests. In a study involving a small group of bracing people, investigators found that the drug - also known as MDMA - prompted heightened feelings of friendliness, playfulness and love, and induced a lowering of the protection that might have therapeutic uses for improving public interactions. Yet the closeness it sparks might not be result in deep and lasting connections.
The findings "suggest that MDMA enhances sociability, but does not by definition increase empathy," noted study author Gillinder Bedi, an helpmate professor of clinical psychology at Columbia University and a research scientist at the New York State Psychiatric Institute in New York City. The study, funded by the US National Institute on Drug Abuse and conducted at the Human Behavioral Pharmacology Laboratory at the University of Chicago, was published in the Dec 15 2010 originate of Biological Psychiatry.
In July, another den reported that MDMA might be advantageous in treating post-traumatic force disorder (PTSD), based on the drug's plain boosting of the ability to cope with grief by helping to control fears without numbing race emotionally. MDMA is part of a family of so-called "club drugs," which are popular with some teens and boyish at all night dances or "raves".
These drugs, which are often used in combination with alcohol, have potentially life-threatening effects, according to the US National Institute on Drug Abuse. The newest muse about explored the slang shit of MDMA on 21 healthy volunteers, nine women and 12 men elderly 18 to 38. All said they had taken MDMA for recreational purposes at least twice in their lives.
They were randomly assigned to board either a low or moderate dose of MDMA, methamphetamine or a sugar cough drop during four sessions in about a three-week period. Each session lasted at least 4,5 hours, or until all paraphernalia of the drug had worn off. During that time, participants stayed in a laboratory testing room, and common interaction was limited to contact with a research assistant who helped distribute cognitive exams.
Sunday 3 February 2019
Marijuana Affects The Index IQ
Marijuana Affects The Index IQ.
A altered analysis challenges preceding research that suggested teens put their long-term brainpower in danger when they smoke marijuana heavily. Instead, the breakdown indicated that the earlier findings could have been thrown off by another factor - the effect of inadequacy on IQ. The author of the new analysis, Ole Rogeberg, cautioned that his theory may not hold much water. "Or, it may revolution out that it explains a lot," said Rogeberg, a research economist at the Ragnar Frisch Center for Economic Research in Oslo, Norway.
The authors of the opening study responded to a plea for comment with a joint statement saying they stand by their findings. "While Dr Rogeberg's ideas are interesting, they are not supported by our data," wrote researchers Terrie Moffitt, Avshalom Caspi and Madeline Meier. Moffitt and Caspi are constitution professors at Duke University, while Meier is a postdoctoral confidant there.
Their study, published in August in the Proceedings of the National Academy of Sciences, attracted media notice because it suggested that smoking cook-pot has more than short-term effects on how people think. Based on an assay of mental tests given to more than 1000 New Zealanders when they were 13 and 38, the Duke researchers found that those who heavily reach-me-down marijuana as teens lost an average of eight IQ points over that time period.
It didn't seem to trouble if the teens later cut back on smoking pot or stopped using it entirely. In the direct term, people who use marijuana have memory problems and trouble focusing, research has shown. So, why wouldn't users have problems for years?
A altered analysis challenges preceding research that suggested teens put their long-term brainpower in danger when they smoke marijuana heavily. Instead, the breakdown indicated that the earlier findings could have been thrown off by another factor - the effect of inadequacy on IQ. The author of the new analysis, Ole Rogeberg, cautioned that his theory may not hold much water. "Or, it may revolution out that it explains a lot," said Rogeberg, a research economist at the Ragnar Frisch Center for Economic Research in Oslo, Norway.
The authors of the opening study responded to a plea for comment with a joint statement saying they stand by their findings. "While Dr Rogeberg's ideas are interesting, they are not supported by our data," wrote researchers Terrie Moffitt, Avshalom Caspi and Madeline Meier. Moffitt and Caspi are constitution professors at Duke University, while Meier is a postdoctoral confidant there.
Their study, published in August in the Proceedings of the National Academy of Sciences, attracted media notice because it suggested that smoking cook-pot has more than short-term effects on how people think. Based on an assay of mental tests given to more than 1000 New Zealanders when they were 13 and 38, the Duke researchers found that those who heavily reach-me-down marijuana as teens lost an average of eight IQ points over that time period.
It didn't seem to trouble if the teens later cut back on smoking pot or stopped using it entirely. In the direct term, people who use marijuana have memory problems and trouble focusing, research has shown. So, why wouldn't users have problems for years?
Saturday 2 February 2019
The Number Of People With Dementia Increases
The Number Of People With Dementia Increases.
The tons of plebeians worldwide living with dementia could more than triple by 2050, a new report reveals. Currently, an estimated 44 million the crowd worldwide have dementia. That number is expected to achieve 76 million in 2030 and 135 million by 2050. Those estimates come from an Alzheimer's Disease International (ADI) plan brief for the upcoming G8 Dementia Summit in London, England.
The projected compute of people with dementia in 2050 is now 17 percent higher than ADI estimated in the 2009 World Alzheimer Report. The further policy brief also predicts a corps in the worldwide distribution of dementia cases, from the richest nations to middle- and low-income countries. By 2050, 71 percent of public with dementia will live in middle- and low-income nations, according to the experts.
The tons of plebeians worldwide living with dementia could more than triple by 2050, a new report reveals. Currently, an estimated 44 million the crowd worldwide have dementia. That number is expected to achieve 76 million in 2030 and 135 million by 2050. Those estimates come from an Alzheimer's Disease International (ADI) plan brief for the upcoming G8 Dementia Summit in London, England.
The projected compute of people with dementia in 2050 is now 17 percent higher than ADI estimated in the 2009 World Alzheimer Report. The further policy brief also predicts a corps in the worldwide distribution of dementia cases, from the richest nations to middle- and low-income countries. By 2050, 71 percent of public with dementia will live in middle- and low-income nations, according to the experts.
Monday 26 November 2018
Gene Therapy Is Promising For The Treatment Of HIV
Gene Therapy Is Promising For The Treatment Of HIV.
Researchers dispatch they've moved a spoor closer to treating HIV patients with gene psychotherapy that could potentially one day keep the AIDS-causing virus at bay. The study, published in the June 16 children of the journal Science Translational Medicine, only looked at one step of the gene psychoanalysis process, and there's no guarantee that genetically manipulating a patient's own cells will be heir or work better than existing drug therapies. Still, "we demonstrated that we could make this happen," said bookwork lead author David L DiGiusto, a biologist and immunologist at City of Hope, a clinic and research center in Duarte, Calif.
And the research took place in people, not in check-up tubes. Scientists are considering gene therapy as a treatment for a variety of diseases, including cancer. One path involves inserting engineered genes into the body to change its response to illness. In the green study, researchers genetically manipulated blood cells to resist HIV and inserted them into four HIV-positive patients who had lymphoma, a blood cancer.
The patients' fit blood cells had been stored earlier and were being transplanted to expound the lymphoma. Ideally, the cells would multiply and fight off HIV infection. In that case, "the virus has nowhere to grow, no fashion to expand in the patient". At this antediluvian point in the research process, however, the goal was to see if the implanted cells would survive. They did, extant in the bloodstreams of the subjects for two years.
Researchers dispatch they've moved a spoor closer to treating HIV patients with gene psychotherapy that could potentially one day keep the AIDS-causing virus at bay. The study, published in the June 16 children of the journal Science Translational Medicine, only looked at one step of the gene psychoanalysis process, and there's no guarantee that genetically manipulating a patient's own cells will be heir or work better than existing drug therapies. Still, "we demonstrated that we could make this happen," said bookwork lead author David L DiGiusto, a biologist and immunologist at City of Hope, a clinic and research center in Duarte, Calif.
And the research took place in people, not in check-up tubes. Scientists are considering gene therapy as a treatment for a variety of diseases, including cancer. One path involves inserting engineered genes into the body to change its response to illness. In the green study, researchers genetically manipulated blood cells to resist HIV and inserted them into four HIV-positive patients who had lymphoma, a blood cancer.
The patients' fit blood cells had been stored earlier and were being transplanted to expound the lymphoma. Ideally, the cells would multiply and fight off HIV infection. In that case, "the virus has nowhere to grow, no fashion to expand in the patient". At this antediluvian point in the research process, however, the goal was to see if the implanted cells would survive. They did, extant in the bloodstreams of the subjects for two years.
Thursday 4 January 2018
The Past Year Has Brought Many Discoveries In The Study Of Diabetes
The Past Year Has Brought Many Discoveries In The Study Of Diabetes.
Even as the forewarning of diabetes continues to grow, scientists have made significant discoveries in the since year that might one light of day lead to ways to stop the blood sugar infirmity in its tracks. That's some good news as World Diabetes Day is observed this Sunday. Created in 1991 as a intersection project between the International Diabetes Federation and the World Health Organization to unseat more attention to the public health threat of diabetes, World Diabetes Day was officially recognized by the United Nations in 2007.
One of the more alluring findings in type 1 diabetes research this year came from the lab of Dr Pere Santamaria at University of Calgary, where researchers developed a vaccine that successfully reversed diabetes in mice. What's more, the vaccine was able to aim only those inoculated cells that were guilty for destroying the insulin-producing beta cells in the pancreas. "The hope is that this work will translate to humans," said Dr Richard Insel, first scientific officer for the Juvenile Diabetes Research Foundation. "And what's invigorating is that they've opened up some pathways we didn't even know were there".
The other avenue of genre 1 research that Insel said has progressed significantly this year is in beta room function. Pedro Herrera, at the University of Geneva Medical School, and his team found that the adult pancreas can literally regenerate alpha cells into functioning beta cells. Other researchers, according to Insel, have been able to reprogram other cells in the body into beta cells, such as the acinar cells in the pancreas and cells in the liver.
This quintessence of apartment manipulation is called reprogramming, a different and less complex process than creating induced pluripotent check cells, so there are fewer potential problems with the process. Another exciting development that came to realization this past year was in type 1 diabetes management. The first closed bend artificial pancreas system was officially tested, and while there's still a long way to go in the regulatory process, Insel said there have been "very favourable results".
Unfortunately, not all diabetes news this past year was sterling news. One of the biggest stories in type 2 diabetes was the US Food and Drug Administration's settlement to restrict the sale of the type 2 diabetes medication rosiglitazone (Avandia) surrounded by concerns that the drug might increase the risk of cardiovascular complications. The manufacturer of Avandia, GlaxoSmithKline, was also ordered to get an unaligned review of clinical trials run by the company.
Even as the forewarning of diabetes continues to grow, scientists have made significant discoveries in the since year that might one light of day lead to ways to stop the blood sugar infirmity in its tracks. That's some good news as World Diabetes Day is observed this Sunday. Created in 1991 as a intersection project between the International Diabetes Federation and the World Health Organization to unseat more attention to the public health threat of diabetes, World Diabetes Day was officially recognized by the United Nations in 2007.
One of the more alluring findings in type 1 diabetes research this year came from the lab of Dr Pere Santamaria at University of Calgary, where researchers developed a vaccine that successfully reversed diabetes in mice. What's more, the vaccine was able to aim only those inoculated cells that were guilty for destroying the insulin-producing beta cells in the pancreas. "The hope is that this work will translate to humans," said Dr Richard Insel, first scientific officer for the Juvenile Diabetes Research Foundation. "And what's invigorating is that they've opened up some pathways we didn't even know were there".
The other avenue of genre 1 research that Insel said has progressed significantly this year is in beta room function. Pedro Herrera, at the University of Geneva Medical School, and his team found that the adult pancreas can literally regenerate alpha cells into functioning beta cells. Other researchers, according to Insel, have been able to reprogram other cells in the body into beta cells, such as the acinar cells in the pancreas and cells in the liver.
This quintessence of apartment manipulation is called reprogramming, a different and less complex process than creating induced pluripotent check cells, so there are fewer potential problems with the process. Another exciting development that came to realization this past year was in type 1 diabetes management. The first closed bend artificial pancreas system was officially tested, and while there's still a long way to go in the regulatory process, Insel said there have been "very favourable results".
Unfortunately, not all diabetes news this past year was sterling news. One of the biggest stories in type 2 diabetes was the US Food and Drug Administration's settlement to restrict the sale of the type 2 diabetes medication rosiglitazone (Avandia) surrounded by concerns that the drug might increase the risk of cardiovascular complications. The manufacturer of Avandia, GlaxoSmithKline, was also ordered to get an unaligned review of clinical trials run by the company.
Thursday 20 August 2015
New Ways To Treat Pancreatic Cancer
New Ways To Treat Pancreatic Cancer.
Scientists are working to acquire unusual ways to treat pancreatic cancer, one of the deadliest types of cancer in the United States. Pancreatic cancer is the fourth prime cause of cancer death in the country. Each year, more than 46000 Americans are diagnosed with the disorder and more than 39000 die from it, according to the US National Cancer Institute. Current treatments allow for drugs, chemotherapy, surgery and radiation therapy, but the five-year survival merit is only about 5 percent. That's in part because it often isn't diagnosed until after it has spread.
And "Today we differentiate more about this form of cancer. We know it usually starts in the pancreatic ducts and that the KRAS gene is mutated in tumor samples from most patients with pancreatic cancer," Dr Abhilasha Nair, an oncologist with the US Food and Drug Administration, said in an operation message release. Scientists are bothersome to develop drugs that target the KRAS mutation, the FDA noted. "Getting the right upper to target the right mutation would be a big break for treating patients with pancreatic cancer.
Scientists are working to acquire unusual ways to treat pancreatic cancer, one of the deadliest types of cancer in the United States. Pancreatic cancer is the fourth prime cause of cancer death in the country. Each year, more than 46000 Americans are diagnosed with the disorder and more than 39000 die from it, according to the US National Cancer Institute. Current treatments allow for drugs, chemotherapy, surgery and radiation therapy, but the five-year survival merit is only about 5 percent. That's in part because it often isn't diagnosed until after it has spread.
And "Today we differentiate more about this form of cancer. We know it usually starts in the pancreatic ducts and that the KRAS gene is mutated in tumor samples from most patients with pancreatic cancer," Dr Abhilasha Nair, an oncologist with the US Food and Drug Administration, said in an operation message release. Scientists are bothersome to develop drugs that target the KRAS mutation, the FDA noted. "Getting the right upper to target the right mutation would be a big break for treating patients with pancreatic cancer.
Subscribe to:
Posts (Atom)